Last reviewed · How we verify
NCT05116137: RESIST
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
NA trial testing Circuit-based resistance exercise (CRT) in Glioblastoma Multiforme of Brain in 24 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 24 |
| Start date | 1 March 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Circuit-based resistance exercise (CRT)
Conditions studied
- Glioblastoma Multiforme of Brain — all drugs for Glioblastoma Multiforme of Brain →
- Brain Cancer — all drugs for Brain Cancer →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
18 and older, any sex, with Glioblastoma Multiforme of Brain or Brain Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise literature and explore the role of a tailored circuit-based resistance training program on functional fitness (i.e., ability to carry out tasks of daily living) and associated health outcomes (e.g., quality of life) for GBM patients on active treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Impact of Resistance Exercise on Muscle Mass in Glioblastoma in Survivors (RESIST): Protocol for a Randomized Controlled Trial.
Keats MR, Grandy SA, Blanchard C, Fowles JR, et al · · 2022 · cited 12× · PMID 35507403 · DOI 10.2196/37709 -
A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.
Puig-Saenz C, Pearson JRD, Thomas JE, McArdle SEB. · · 2023 · cited 4× · PMID 37626597 · DOI 10.3390/biomedicines11082100 -
Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy.
Xie L, Wang F. · · 2025 · cited 1× · PMID 40809025 · DOI 10.3389/fonc.2025.1638060
Verify or expand the search:
- PubMed search for NCT05116137
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma Multiforme of Brain
Currently open trials in the same condition.
- NCT06815432 — GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma · Phase 1 · recruiting
- NCT06613841 — Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma · EARLY_PHASE1 · recruiting
- NCT06283927 — The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) · recruiting
- NCT06273176 — The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma · recruiting
- NCT06146725 — The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) · recruiting
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05116137 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116137.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing